Profarma (PFRM3) began, on November 19, 2026, a planned succession process for the positions of Chief Financial Officer (CFO) and Investor Relations Officer (IRO), currently held by Maximiliano Guimarães Fischer. On that date, the Board of Directors elected Augusto Passmann Ribeiro da Costa as Officer without specific designation, with a term through May 31, 2027, coinciding with that of the other members of the Executive Board.

The election is part of the succession plan and seeks to ensure an orderly, gradual transition of the responsibilities of the finance and investor relations areas. During this period, Augusto will follow and support these activities, including interaction with shareholders, investors, analysts and other capital markets participants.

After more than 30 years at Grupo Profarma, 25 of them as CFO and 20 as IRO, Fischer will remain on the Statutory Board as Vice President. He will take part in the group's strategic projects and will lead the Tax, Fiscal, Risk Management and Internal Controls areas.

Augusto holds an MBA from Bayes Business School in London and has more than 25 years of experience in corporate finance, M&A, capital markets, auditing and risk management. He was chief financial officer of Grupo Malwee (2021–2026), Profarma Specialty and d1000 Varejo Farma Participações, and also worked in valuation at Rio Tinto in London.

Augusto's appointment to the CFO and IRO positions is expected to be decided by the Board of Directors by the end of the current fiscal year, subject to the applicable corporate procedures and regulations.

Source: Notice to the Market, filed with the CVM on 11/19/2026 19:12. View original document

For information only; not investment advice.

Is PFRM3 worth investing in?

PFRM3Profarma Distribuição · B3
Price
R$ 7.48
as of 11/18/2026
Dividend yield
6.43 %
P/L
6.04
P/VPA
0.62
View full analysis of PFRM3